Medtronic celebrates renal denervation hypertension data; Given Imaging touts GI imaging results;

 @FierceMedDev: Israel's growing medical device industry gains a public stage this week. More | Follow @FierceMedDev

 @MarkHFierce: W.L. Gore has the final piece in place for its REDUCE Clinical study, to test a new stroke prevention device. More | Follow @MarkHFierce

 @DamianFierce: WuXi AppTec is making a splash in biologics, launching a cGMP plant in China. More | Follow @DamianFierce

> Medtronic ($MDT) says it has generated major, long-term reductions in high blood pressure over two years in patients treated with the company's Symplicity renal denervation system. Item

> Israel's InSightec nailed down FDA approval to use its ExAblate MRI-guided focused ultrasound device to treat pain from bone metastases in patients who don't respond to or can't use radiation treatment for their pain. Item

> An analyst firm has launched a new study on how physicians and other medical professionals are taught to use new medical devices. Item

> French company Nicox is debuting its point-of-care diagnostic for acute conjunctivitis in the U.S. Item

> Given Imaging ($GIVN) is touting new studies it says shows the benefit of using high-resolution manometry to diagnose patients with anorectal and GI reflux disorders. Release

> California diagnostics startup Natera wants to change prenatal testing by analyzing DNA fragments. Story

Biotech News

 @FierceBiotech: Researchers seek new pancreatic cancer biomarkers. Item | Follow @FierceBiotech

 @JohnCFierce: In case you missed it Friday, my analysis on Q3 venture numbers (good) and top 10 deals of the quarter. Special Report | Follow @JohnCFierce

 @RyanMFierce: Quintiles reels in pharma business with IT game changers. More | Follow @RyanMFierce

> Orexigen says FDA nods support for a speedy review of Contrave. More

> Genzyme pays $22.5M upfront to bag Asian rights to Alnylam's hot ATTR program. Report

> Bayer nails promising PhIII results for new PAH contender riociguat. News

Pharma News

@FiercePharma: Merck is a champion donor, charity pub says. Ranks 2nd for corporate giving, as % of pretax profits.--Forbes. More | Follow @FiercePharma

> Pfizer snags new ADHD drug in $680M NextWave deal. Story

> Novartis balks at Eylea-vs.-Lucentis data. Article

> Turkey eyes a $23B pharma sector by 2023, up from $5B. News

> Generic savings tell a different patent-loss tale. Report

CRO News

> Lundbeck seeks partners on Alzheimer's drug after EMA rejection. Item

> Korean group enlists WCCT to spur drug development. More

> WuXi launches China's first GMP-friendly biologics plant. News

> Catalent looks to bridge industry, academia on drug delivery. Article

Biotech IT News

> Pfizer wins popularity contest in social media survey of patients. More

> Quintiles reels in pharma business with IT game changers. Story

> Appistry grabs distribution of MIT-Harvard genome toolkit. Report

> Big Pharma consortium to share cancer trial data. Article